AU2015311681B2 - Globin gene therapy for treating hemoglobinopathies - Google Patents
Globin gene therapy for treating hemoglobinopathies Download PDFInfo
- Publication number
- AU2015311681B2 AU2015311681B2 AU2015311681A AU2015311681A AU2015311681B2 AU 2015311681 B2 AU2015311681 B2 AU 2015311681B2 AU 2015311681 A AU2015311681 A AU 2015311681A AU 2015311681 A AU2015311681 A AU 2015311681A AU 2015311681 B2 AU2015311681 B2 AU 2015311681B2
- Authority
- AU
- Australia
- Prior art keywords
- region
- expression cassette
- globin
- seq
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021290257A AU2021290257A1 (en) | 2014-09-04 | 2021-12-21 | Globin gene therapy for treating hemoglobinopathies |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462045997P | 2014-09-04 | 2014-09-04 | |
US62/045,997 | 2014-09-04 | ||
PCT/US2015/048698 WO2016037138A1 (en) | 2014-09-04 | 2015-09-04 | Global gene therapy for treating hemoglobinopathies |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021290257A Division AU2021290257A1 (en) | 2014-09-04 | 2021-12-21 | Globin gene therapy for treating hemoglobinopathies |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2015311681A1 AU2015311681A1 (en) | 2017-04-13 |
AU2015311681A8 AU2015311681A8 (en) | 2019-08-08 |
AU2015311681B2 true AU2015311681B2 (en) | 2021-09-23 |
Family
ID=55440425
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015311681A Active AU2015311681B2 (en) | 2014-09-04 | 2015-09-04 | Globin gene therapy for treating hemoglobinopathies |
AU2021290257A Pending AU2021290257A1 (en) | 2014-09-04 | 2021-12-21 | Globin gene therapy for treating hemoglobinopathies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021290257A Pending AU2021290257A1 (en) | 2014-09-04 | 2021-12-21 | Globin gene therapy for treating hemoglobinopathies |
Country Status (11)
Country | Link |
---|---|
US (2) | US11717579B2 (zh) |
EP (2) | EP3189143B1 (zh) |
JP (3) | JP6710680B2 (zh) |
KR (2) | KR102500531B1 (zh) |
CN (3) | CN114457076A (zh) |
AU (2) | AU2015311681B2 (zh) |
BR (1) | BR112017004349A2 (zh) |
CA (1) | CA2960209C (zh) |
ES (1) | ES2746529T3 (zh) |
MX (1) | MX2017002900A (zh) |
WO (1) | WO2016037138A1 (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6737714B2 (ja) | 2014-03-14 | 2020-08-12 | ユニヴァーシティ オブ ワシントン | ゲノムインスレーターエレメントおよびその使用 |
EP3548617A4 (en) | 2016-12-05 | 2020-06-17 | The Regents of The University of California | LENTIVIRAL VECTOR OPTIMIZED FOR HEMOGLOBINOPATHY STEM CELL THERAPY |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
WO2018183692A1 (en) * | 2017-03-29 | 2018-10-04 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
EP3635120A1 (en) * | 2017-06-02 | 2020-04-15 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder |
AU2018378683A1 (en) * | 2017-12-06 | 2020-07-02 | Memorial Sloan-Kettering Cancer Center | Globin gene therapy for treating hemoglobinopathies |
WO2019213011A1 (en) * | 2018-04-30 | 2019-11-07 | The Children's Hospital Of Philadelphia | Compositions and methods for hemoglobin production |
EP3886869A4 (en) * | 2018-11-28 | 2022-07-06 | Forty Seven, Inc. | GENETICALLY MODIFIED CSPH RESISTANT TO ABLATIVE TREATMENT |
EP3924376A4 (en) * | 2019-02-14 | 2022-12-14 | The Regents Of The University Of California | OPTIMIZED LENTIVIRAL VECTOR COMPRISING MINIMUM ENABLING SEQUENCE ELEMENTS FOR HEMOGLOBINOPATHY STEM CELL GENE THERAPY |
EP3931338A4 (en) * | 2019-02-28 | 2023-01-11 | The Regents Of The University Of California | LENTIVIRAL VECTOR ENHANCEMENT SYSTEMS (CCLC-MGATA/ANK-CORE LCR-BETA-AS3-FB) TO INCREASE EXPRESSION |
CN110042124A (zh) * | 2019-04-25 | 2019-07-23 | 国家卫生健康委科学技术研究所 | 基因组碱基编辑增加人红细胞中胎儿血红蛋白水平的试剂盒及应用 |
CN109999053B (zh) * | 2019-04-26 | 2021-03-23 | 周德旺 | 曲氟尿苷或曲氟尿苷替匹嘧啶组合物的医药用途 |
CN110106203B (zh) * | 2019-05-24 | 2023-08-11 | 中国医学科学院血液病医院(血液学研究所) | 一种新型hbb过表达载体及其设计方法和应用 |
CN110699381A (zh) * | 2019-09-17 | 2020-01-17 | 合肥瑞灵生物科技有限公司 | 地中海贫血病基因治疗载体构建方法及其用途 |
EP4093442A4 (en) * | 2020-01-22 | 2024-05-29 | Altius Inst For Biomedical Sciences | NOVEL ERYTHROD-SPECIFIC ENHANCERS AND THEIR USES |
JP7031690B2 (ja) * | 2020-01-27 | 2022-03-08 | 株式会社三洋物産 | 遊技機 |
WO2022212720A1 (en) * | 2021-03-31 | 2022-10-06 | Sigilon Therapeutics, Inc. | Genetically modified human cell lines and uses thereof |
CN113106098B (zh) * | 2021-04-21 | 2022-04-01 | 贵州医科大学 | 一种在红系细胞中特异表达人β珠蛋白的重组序列及其应用 |
CN113564248A (zh) * | 2021-09-26 | 2021-10-29 | 北京贝瑞和康生物技术有限公司 | 同时检测hba1/2、hbb和hbd基因位点多种突变的方法和试剂盒 |
CN114457119B (zh) * | 2022-04-11 | 2022-08-12 | 中吉智药(南京)生物技术有限公司 | 慢病毒载体在制备治疗β-地中海贫血药物中的应用 |
CN116271106B (zh) * | 2023-05-24 | 2023-08-11 | 中吉智药(南京)生物技术有限公司 | 慢病毒载体LentilAlpha在制备治疗α-地中海贫血药物中的应用 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
DK0641192T3 (da) | 1992-05-18 | 1998-03-02 | Minnesota Mining & Mfg | Anordning til transmucosal lægemiddelafgivelse |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
IL178921A0 (en) | 1998-12-24 | 2007-03-08 | Yeda Res & Dev | Caspase-8 interacting proteins |
BR0211307A (pt) | 2001-06-29 | 2004-09-14 | Sloan Kettering Inst Cancer | Lentivetor recombinante codificando o gene da globina humana, uso do mesmo no tratamento de hemoglobinopatias, células de mamìfero oriundas do progenitor hematopoietico e método para preparo de uma composição terapêutica para tratamento de hemoglobinopatia em um mamìfero |
WO2004005458A2 (en) * | 2002-06-13 | 2004-01-15 | Regulome Corporation | Functional sites |
US20080069805A1 (en) * | 2005-05-18 | 2008-03-20 | Williams Bruce M | Use of stem cells to cure genetic diseases in humans cure for sickle cell anemia |
WO2008101216A2 (en) * | 2007-02-15 | 2008-08-21 | The Govt. Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services | Gamma satellite insulator sequences and their use in preventing gene silencing |
US8790345B2 (en) | 2007-08-21 | 2014-07-29 | Zimmer, Inc. | Titanium alloy with oxidized zirconium for a prosthetic implant |
US20090156534A1 (en) * | 2007-09-13 | 2009-06-18 | Memorial Sloan-Kettering Cancer Center | Globin lentiviral vectors for treatment of disease |
WO2010046493A2 (en) * | 2008-10-23 | 2010-04-29 | Université de Lausanne | Gene transfer vectors comprising at least one isolated dna molecule having insulator and or boundary properties and methods to identify the same |
EP2414524B1 (en) * | 2009-04-03 | 2017-08-23 | Centre National De La Recherche Scientifique | Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements |
CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
CA2879578A1 (en) | 2012-08-03 | 2014-02-06 | Abb Technology Ag | Overload limitation in peak power operation |
US20150216903A1 (en) * | 2012-08-10 | 2015-08-06 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
US8823480B2 (en) | 2012-08-10 | 2014-09-02 | Tyco Electronics Corporation | Planar electronic device |
US20150224209A1 (en) * | 2012-09-14 | 2015-08-13 | The Regents Of The University Of California | Lentiviral vector for stem cell gene therapy of sickle cell disease |
US10072067B2 (en) * | 2014-01-30 | 2018-09-11 | Children's Hospital Medical Center | Fetal hemoglobin for genetic correction of sickle cell disease |
JP6737714B2 (ja) * | 2014-03-14 | 2020-08-12 | ユニヴァーシティ オブ ワシントン | ゲノムインスレーターエレメントおよびその使用 |
-
2015
- 2015-09-04 EP EP15837740.8A patent/EP3189143B1/en active Active
- 2015-09-04 CN CN202210122741.1A patent/CN114457076A/zh active Pending
- 2015-09-04 KR KR1020177008935A patent/KR102500531B1/ko active IP Right Grant
- 2015-09-04 KR KR1020237005064A patent/KR20230030002A/ko not_active Application Discontinuation
- 2015-09-04 AU AU2015311681A patent/AU2015311681B2/en active Active
- 2015-09-04 EP EP19185730.9A patent/EP3620521B1/en active Active
- 2015-09-04 BR BR112017004349A patent/BR112017004349A2/pt not_active Application Discontinuation
- 2015-09-04 WO PCT/US2015/048698 patent/WO2016037138A1/en active Application Filing
- 2015-09-04 ES ES15837740T patent/ES2746529T3/es active Active
- 2015-09-04 CN CN201580060160.8A patent/CN107208093B/zh active Active
- 2015-09-04 JP JP2017512966A patent/JP6710680B2/ja active Active
- 2015-09-04 CA CA2960209A patent/CA2960209C/en active Active
- 2015-09-04 CN CN202210122739.4A patent/CN114480393A/zh active Pending
- 2015-09-04 MX MX2017002900A patent/MX2017002900A/es unknown
-
2017
- 2017-03-03 US US15/449,416 patent/US11717579B2/en active Active
-
2020
- 2020-03-03 JP JP2020035649A patent/JP7158427B2/ja active Active
-
2021
- 2021-12-21 AU AU2021290257A patent/AU2021290257A1/en active Pending
-
2022
- 2022-06-01 JP JP2022089526A patent/JP2022107736A/ja active Pending
-
2023
- 2023-01-26 US US18/160,083 patent/US20240066148A1/en active Pending
Non-Patent Citations (1)
Title |
---|
"Homo sapiens chromosome 1 clone RP11-550H2, complete sequence.", EMBL, (2001-07-31), Database accession no. AC092813, URL: EBI * |
Also Published As
Publication number | Publication date |
---|---|
AU2015311681A1 (en) | 2017-04-13 |
CN114457076A (zh) | 2022-05-10 |
US20170173185A1 (en) | 2017-06-22 |
EP3189143B1 (en) | 2019-08-07 |
WO2016037138A1 (en) | 2016-03-10 |
EP3620521B1 (en) | 2024-05-29 |
ES2746529T3 (es) | 2020-03-06 |
JP2022107736A (ja) | 2022-07-22 |
JP7158427B2 (ja) | 2022-10-21 |
KR20170044752A (ko) | 2017-04-25 |
US20240066148A1 (en) | 2024-02-29 |
AU2021290257A1 (en) | 2022-01-27 |
JP2017532023A (ja) | 2017-11-02 |
CN114480393A (zh) | 2022-05-13 |
EP3189143A1 (en) | 2017-07-12 |
EP3620521A1 (en) | 2020-03-11 |
US11717579B2 (en) | 2023-08-08 |
CA2960209A1 (en) | 2016-03-10 |
JP6710680B2 (ja) | 2020-06-17 |
BR112017004349A2 (pt) | 2017-12-05 |
MX2017002900A (es) | 2017-10-24 |
EP3189143A4 (en) | 2018-03-21 |
AU2015311681A8 (en) | 2019-08-08 |
KR102500531B1 (ko) | 2023-02-17 |
WO2016037138A8 (en) | 2017-03-16 |
JP2020079327A (ja) | 2020-05-28 |
CA2960209C (en) | 2023-08-29 |
KR20230030002A (ko) | 2023-03-03 |
CN107208093B (zh) | 2022-03-01 |
CN107208093A (zh) | 2017-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240066148A1 (en) | Globin gene therapy for treating hemoglobinopathies | |
Staal et al. | Autologous stem-cell-based gene therapy for inherited disorders: state of the art and perspectives | |
US11753654B2 (en) | Globin gene therapy for treating hemoglobinopathies | |
WO2020149395A1 (ja) | 栄養障害型表皮水疱症治療薬 | |
Drakopoulou et al. | Towards more successful gene therapy clinical trials for β-thalassemia | |
US20220056484A1 (en) | Selection by means of artificial transactivators | |
CN110678553B (zh) | 在哺乳动物干细胞中进行基因组编辑的方法 | |
US20220280571A1 (en) | Compositions and methods for treating alpha thalassemia | |
US20220401489A1 (en) | Compositions and methods for treating sickle cell disease | |
CN114072518B (zh) | 用于治疗地中海贫血或镰状细胞病的方法和组合物 | |
Gorter | Retroviral vectors and transposons for stable gene therapy and manufacturing vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH | Corrigenda |
Free format text: IN VOL 31 , NO 14 , PAGE(S) 2137 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME UNIVERSITY OF WASHINGTON; MEMORIAL SLOAN-KETTERING CANCER CENTER, APPLICATION NO. 2015311681, UNDER INID (72) CORRECT THE CO-INVENTOR TO SADELAIN, MICHEL |
|
FGA | Letters patent sealed or granted (standard patent) |